| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/31/2001 | EP1071446A2 Regulation of ovarian maturation and function using epidermal growth factor |
| 01/31/2001 | EP1071445A2 Therapeutic angiogenic factors and methods for their use |
| 01/31/2001 | EP1071443A1 Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof |
| 01/31/2001 | EP1071442A1 Methods and compositions for peptide synthesis |
| 01/31/2001 | EP1071434A1 Cnre binding factors and uses thereof |
| 01/31/2001 | EP1071433A2 Pharmaceutical composition |
| 01/31/2001 | EP1071415A2 Flutamide compositions and preparations |
| 01/31/2001 | EP1071408A1 Microparticles for drug delivery across mucosa and the blood-brain barrier |
| 01/31/2001 | EP1071407A1 Lipophilic microparticles containing a protein drug or antigen and formulation comprising same |
| 01/31/2001 | EP1071400A1 Drug delivery of proteins from polymeric blends |
| 01/31/2001 | EP1071333A1 Induction of immunity against tumor self-antigens |
| 01/31/2001 | EP0610356B1 Treatment of bacterial dysentery |
| 01/31/2001 | CN1282372A Mammalian sytokine-like polypeptide-10 |
| 01/31/2001 | CN1282371A Ac (DNA encoding C6 beta-chemokine leukotactin-1 (Lkn-1) isolated from human |
| 01/31/2001 | CN1282345A Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/31/2001 | CN1282338A A DNA molecule encoding mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof |
| 01/31/2001 | CN1282337A Cyclopeptide derivatives with integrin inhibitor properties |
| 01/31/2001 | CN1282336A Hemiasterlin analogs |
| 01/31/2001 | CN1282255A IFNAR2/I FN complex |
| 01/31/2001 | CN1282254A Compositions and methods for regulating phagocytosis and ICAM-1 expression |
| 01/31/2001 | CN1282253A Small peptides and method for treatment of asthma and inflammation |
| 01/31/2001 | CN1282218A Compositions and method for treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 01/31/2001 | CN1281727A Antiviral composite containing phycocyanin extract and extraction of phycocyanin |
| 01/31/2001 | CN1061373C Method for preparing monomer insulin |
| 01/31/2001 | CN1061339C Novel sulfonamide inhibitors of aspartyl protease |
| 01/30/2001 | US6180773 The cc type chemokines belong to a family of polypeptides which have proven to be mediators of immune reactions, and which have antiviral activity with respect to hiv |
| 01/30/2001 | US6180772 Nucleic acids encoding dominant negative I-κ-B -α polypeptides |
| 01/30/2001 | US6180771 Given nucleotide sequence; useful for pharmaceutical administration or methods of diagnosing sensitivity to house dust mites |
| 01/30/2001 | US6180759 Process for the preparation of azacycloalkylakanoyl pseudotetrapeptides |
| 01/30/2001 | US6180679 Parasiticide |
| 01/30/2001 | US6180666 Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
| 01/30/2001 | US6180665 Crystalline polymorphic form of (S,S,S)-N-(1-[2-carboxy-3 (N2-mesyllyslamino) propyl]-1- cyclopentylcarbonyl) tyrosine |
| 01/30/2001 | US6180646 Retroviral protease inhibitors |
| 01/30/2001 | US6180634 Combination therapy for the treatment of AIDS |
| 01/30/2001 | US6180631 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds |
| 01/30/2001 | US6180627 Antithrombotic agents |
| 01/30/2001 | US6180619 Prenyl transferase inhibitors |
| 01/30/2001 | US6180614 Methods of immunization of aquaculture species by introducing dna expression systems into the aquaculture species |
| 01/30/2001 | US6180613 AAV-mediated delivery of DNA to cells of the nervous system |
| 01/30/2001 | US6180612 Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives |
| 01/30/2001 | US6180611 Inhibitors of matrix metalloproteinases and tumor necrosis factor |
| 01/30/2001 | US6180610 Tetrapeptide |
| 01/30/2001 | US6180609 Methods for treating LHRH associated disorders with LHRH antagonists |
| 01/30/2001 | US6180608 Packaged formulation for treating a subject for a condition treatable with an lhrh analogue, comprising ionic complex of lhrh analogue and carrier macromolecule |
| 01/30/2001 | US6180607 Employed as therapeutics in diseases such as emphysema, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, cystic fibrosis, rheumatoid arthritis, organ failure, and glomerulonephritis |
| 01/30/2001 | US6180606 Compositions with enhanced osteogenic potential, methods for making the same and uses thereof |
| 01/30/2001 | US6180605 Composition with enhanced osteogenic potential, method for making the same and therapeutic uses thereof |
| 01/30/2001 | US6180604 Compositions and methods for treating infections using analogues of indolicidin |
| 01/30/2001 | US6180603 Method for administering neurologic agents to the brain |
| 01/30/2001 | US6180601 Freeze-dried soft, flexible and continous matrix of hyaluronic acid containing peptide or protein used for wound healing |
| 01/30/2001 | US6180600 CD8 antagonists |
| 01/30/2001 | US6180599 May include lectins and/or fluoride in addition to medium-chain fatty acids; toothpaste, spray, gum |
| 01/30/2001 | US6180598 Covalently modified hemoglobin having low temperature-dependent oxygen-binding function |
| 01/30/2001 | US6180597 Useful in treating or preventing conditions such as pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. |
| 01/30/2001 | US6180596 Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities |
| 01/30/2001 | US6180403 Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| 01/30/2001 | US6180387 Nucleotide sequence coding an enzymatic polypeptide; for the detection of bactericides and batericidal agonist and antagonists which prevent bacterial infection |
| 01/30/2001 | US6180386 DNA sequences coding for the human proteins Tx and Ty related to the interleukin-1beta converting enzyme |
| 01/30/2001 | US6180384 Compounds |
| 01/30/2001 | US6180383 Insect proteolytic enzyme; for the prevention of insect infestation |
| 01/30/2001 | US6180380 Cloning of a new member of the serine threonine kinase family |
| 01/30/2001 | US6180379 Eukaryotic transport protein; for utilization in the ubiquination and degradation of cell cycle polypeptides |
| 01/30/2001 | US6180377 Humanized antibodies |
| 01/30/2001 | US6180371 Modified factor VIII |
| 01/30/2001 | US6180370 Preparing preferential antibodies; generating nucleotide sequences coding preferential antibodies, expressing nucleotide sequences in transformed cell and recovering preferential antibodies |
| 01/30/2001 | US6180369 Varicella-zoster virus antigen |
| 01/30/2001 | US6180365 Expression vector coding membrane binding polypeptide; for use in diagnosis and treatment of bacterial, fungal or viral infection |
| 01/30/2001 | US6180364 Protein called epil/placentin, process for the preparation of this protein and pharmaceutical composition containing such, DNA coding for said protein |
| 01/30/2001 | US6180362 Peptides which inhibit ras protein activity, their preparation and use |
| 01/30/2001 | US6180355 Method for diagnosing and treating chronic pelvic pain syndrome |
| 01/30/2001 | US6180342 Vacuolar proton ATPase subunits |
| 01/30/2001 | US6180336 Labelling and selection of molecules |
| 01/30/2001 | US6180141 Composite gel microparticles as active principle carriers |
| 01/30/2001 | US6180140 Modified amino acids for drug delivery |
| 01/30/2001 | US6180111 Vaccine delivery system |
| 01/30/2001 | US6180104 Can be used such as nucleotide probes, combining with foreign dna sequences to produce novel t-cell receptors, which can be used in an analogous manner as antibodies, or constructs can be provided which provide for extrachromosomal elements |
| 01/30/2001 | US6180103 Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
| 01/30/2001 | US6180097 For treatment of solid tumors, including their metastases, without radiation, surgery or standard chemotherapeutic by using superantigens, including staphyloccocal enterotoxins b and c, to stimulate tumor draining lymph node cells |
| 01/30/2001 | US6180096 Formulations for protection of peg-interferon alpha conjugates |
| 01/30/2001 | US6180095 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 01/30/2001 | CA2272317C Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound |
| 01/30/2001 | CA2139931C Purification of factor ix |
| 01/30/2001 | CA2132953C Monospecific polyclonal antibodies to shiga-like toxins |
| 01/30/2001 | CA2124458C Technetium-99m labeled peptides for imaging |
| 01/30/2001 | CA2101942C Technetium-99m labeled polypeptides for imaging |
| 01/30/2001 | CA2064558C Method for inhibiting growth of stem cells |
| 01/30/2001 | CA2056997C A human cytokine, interleukin-9 |
| 01/30/2001 | CA2052013C Tripeptide antithrombotic agents |
| 01/30/2001 | CA2022610C Human gp130 protein |
| 01/30/2001 | CA1341175C Hydrolysed milk proteins for dialysis procedures |
| 01/30/2001 | CA1341174C Procoagulant proteins derived from factor viii: c |
| 01/29/2001 | CA2314682A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 01/25/2001 | WO2001006756A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 01/25/2001 | WO2001006262A1 Diagnostics and therapeutics for macular degeneration |
| 01/25/2001 | WO2001006015A1 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 01/25/2001 | WO2001006010A1 Antisense modulation of telomeric repeat binding factor 1 expression |
| 01/25/2001 | WO2001005998A1 Follistatin-3 |
| 01/25/2001 | WO2001005990A1 Structural protein of adeno-associated virus with modified antigenicity, its production and its use |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005974A2 The il-1l1 gene and polypeptide products |